<DOC>
	<DOCNO>NCT02265536</DOCNO>
	<brief_summary>The main purpose study learn investigational drug , LY3022855 , affect immune system participant advance breast prostate cancer respond treatment . Treatment may last 6 cycle ( cycle = 6 week ) .</brief_summary>
	<brief_title>A Study LY3022855 In Participants With Breast Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Confirmed diagnosis advance , refractory breast prostate cancer evaluable radiologic testing . Participants must experience tumor progression treatment intolerance least one prior therapy . For participant metastatic castrateresistant prostate cancer : Must continue ongoing androgen deprivation therapy castrate level serum testosterone &lt; 50 nanogram/deciliter ( ng/dL ) If receive antiandrogen part firstline hormonal therapy , must show progression disease antiandrogen prior enrollment Must willing continue androgen deprivation therapy study , prior orchiectomy Must meet least 1 follow 3 criterion progressive metastatic disease , accord Prostate Cancer Working Group 2 ( PCWG2 ) criterion : A rise prostatespecific antigen ( minimal value 2 ng/milliliter ( mL ) ; ≥3 consecutive rise value ) ≥2 new metastasis transaxial image radionuclide bone scan Soft tissue progression Replacement hormone therapy initiate study entry permit For participant breast cancer : May continue ongoing antiestrogen Replacement hormone therapy initiate study entry permit May continue ongoing trastuzumab therapy Have adequate organ function , include : Hepatic : Bilirubin ≤1.5 × upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3.0 × ULN . For participant tumor involvement liver , AST ALT ≤5.0 × ULN acceptable . For participant tumor involvement bone , alkaline phosphatase ≤5.0 × ULN acceptable . Renal : Serum creatinine ≤2.0 × ULN . Absolute neutrophil count ( ANC ) ≥1.0 × 109/liter ( L ) . Hemoglobin ≥9 gram per deciliter ( 5.58 millimoles per liter ) . Platelets ≥90 × 109/L . Have Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Have discontinue diseasemodifying therapy primary cancer &gt; 28 day prior initiation study treatment . In addition , clinically significant toxicity associate prior therapy primary cancer , include investigational treatment , resolve stabilize Grade ≤1 toxicity &gt; 28 day prior initiation study treatment exception neuropathy , must resolve Grade ≤2 . Continuation stable dose ( minimum 28 day prior study entry ) denosumab bisphosphonate permit study . Willing undergo 1 baseline 1 posttreatment tumor biopsy procedure . Male participant : Agree use reliable method birth control donate sperm study least 12 week follow last dose study drug country requirement , whichever longer . Female participant : Are woman childbearing potential test negative pregnancy within 7 day prior enrollment base urine serum pregnancy test agree use reliable method birth control study 12 week follow last dose study drug also must breastfeed , OR postmenopausal woman . Have receive treatment within 28 day prior initial dose study drug investigational product nonapproved use drug device ( study drug/device use study ) noncancer indication concurrently enrol type medical research judge scientifically medically compatible study . Have serious preexist medical condition ( leave discretion investigator ) . Have symptomatic central nervous system ( CNS ) malignancy metastasis . Have active fungal , bacterial , and/or know viral infection , include human immunodeficiency virus ( HIV ) viral ( B C ) hepatitis . Have follow cardiovascular condition : Symptomatic coronary artery disease currently within past 6 month , Confirmed leave ventricular ejection fraction ≤50 % cardiac insufficiency &gt; New York Heart Association ( NYHA ) class II currently within past 6 month , Uncontrolled hypertension ( &gt; 170/100 millimeter mercury [ mm Hg ] ) currently within past 7 day , Serious cardiac arrhythmia ( wellcontrolled atrial fibrillation permit ) currently within past 6 month . Have correct QT interval &gt; 500 millisecond ( msec ) screen electrocardiogram ( ECG ) . Have receive treatment agent specifically target colony stimulate factor 1 ( CSF1 ) CSF1R , include imatinib , nilotinib , sunitinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>